KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Shares Outstanding (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Shares Outstanding for 8 consecutive years, with $245.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding rose 25.2% year-over-year to $245.2 million, compared with a TTM value of $245.2 million through Dec 2025, up 25.2%, and an annual FY2025 reading of $245.2 million, up 25.2% over the prior year.
  • Shares Outstanding was $245.2 million for Q4 2025 at Esperion Therapeutics, up from $205.4 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $245.2 million in Q4 2025 and bottomed at $26.2 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $122.6 million, with a median of $106.5 million recorded in 2023.
  • The sharpest move saw Shares Outstanding dropped 5.32% in 2021, then surged 167.7% in 2022.
  • Year by year, Shares Outstanding stood at $60.9 million in 2021, then grew by 22.49% to $74.6 million in 2022, then surged by 58.52% to $118.2 million in 2023, then surged by 65.68% to $195.9 million in 2024, then grew by 25.2% to $245.2 million in 2025.
  • Business Quant data shows Shares Outstanding for ESPR at $245.2 million in Q4 2025, $205.4 million in Q3 2025, and $200.2 million in Q2 2025.